Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma
Sagar Lonial(Emory University), Shaji Kumar(Mayo Clinic), Cara A. Rosenbaum(Cornell University), Habte Yimer(Texas Oncology), Saulius Girnius(TriHealth), Bo H. Chao(Takeda (United States)), Moshe Levy(Hebrew University of Jerusalem), Rafat Abonour(Sylvester Comprehensive Cancer Center), Omar Nadeem(Harvard University), Meera Mohan(Medical College of Wisconsin), Igor Proscurshim(Takeda (United States)), Vivek Roy(Jacksonville College), Yuhong Zhang(Sun Yat-sen University), Akito Nakamura, Christine K. Ward(Takeda (United States)), Deborah Berg(Millennium Engineering and Integration (United States)), Keli Song(Takeda (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jeremy T. Larsen(City of Hope), Stefano Tarantolo(Houston Methodist), Allison Berger(Takeda (United States))
Cited by 3
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k